Mitiglinide: Difference between revisions

	WikiDoc Resources for Mitiglinide
Articles
Most recent articles on Mitiglinide Most cited articles on Mitiglinide Review articles on Mitiglinide Articles on Mitiglinide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mitiglinide Images of Mitiglinide Photos of Mitiglinide Podcasts & MP3s on Mitiglinide Videos on Mitiglinide
Evidence Based Medicine
Cochrane Collaboration on Mitiglinide Bandolier on Mitiglinide TRIP on Mitiglinide
Clinical Trials
Ongoing Trials on Mitiglinide at Clinical Trials.gov Trial results on Mitiglinide Clinical Trials on Mitiglinide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mitiglinide NICE Guidance on Mitiglinide NHS PRODIGY Guidance FDA on Mitiglinide CDC on Mitiglinide
Books
Books on Mitiglinide
News
Mitiglinide in the news Be alerted to news on Mitiglinide News trends on Mitiglinide
Commentary
Blogs on Mitiglinide
Definitions
Definitions of Mitiglinide
Patient Resources / Community
Patient resources on Mitiglinide Discussion groups on Mitiglinide Patient Handouts on Mitiglinide Directions to Hospitals Treating Mitiglinide Risk calculators and risk factors for Mitiglinide
Healthcare Provider Resources
Symptoms of Mitiglinide Causes & Risk Factors for Mitiglinide Diagnostic studies for Mitiglinide Treatment of Mitiglinide
Continuing Medical Education (CME)
CME Programs on Mitiglinide
International
Mitiglinide en Espanol Mitiglinide en Francais
Business
Mitiglinide in the Marketplace Patents on Mitiglinide
Experimental / Informatics
List of terms related to Mitiglinide

Mitiglinide
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	oral
ATC code	A10BX08 (WHO) ;
Identifiers
	IUPAC name (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol- 2-yl]-4-oxobutanoic acid;
CAS Number	145375-43-5 ;
PubChem CID	121891;
DrugBank	DB01252 ;
ChemSpider	108739 ;
UNII	D86I0XLB13;
KEGG	D01854 ;
ChEMBL	ChEMBL471498 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C19H25NO3
Molar mass	315.41 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3;
	InChI InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 ; Key:WPGGHFDDFPHPOB-BBWFWOEESA-N ;
(what is this?) (verify)

← Older edit Newer edit →

VisualWikitext

Revision as of 18:28, 10 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.^[1]

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.

Dosage

Mitiglinide is delivered in tablet form.

References

↑ Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455.

External links

Elixir Pharmaceuticals - website of the U.S. rights holder for mitiglinide.

Template:Oral hypoglycemics

[pmid18803455-1] Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455.

[1]

@@ Line 1: / Line 1: @@
+{{Drugbox
+| Verifiedfields = changed
+| verifiedrevid = 462252797
+| IUPAC_name = (2''S'')-2-benzyl-4-[(3a''R'',7a''S'')-octahydro-2''H''-isoindol- 2-yl]-4-oxobutanoic acid
+| image = Mitiglinide.svg
+<!--Clinical data-->
+| tradename =
+| Drugs.com = {{drugs.com|international|mitiglinide}}
+| routes_of_administration = oral
-{{drugbox
+<!--Identifiers-->
-| IUPAC_name = (-)-2(''S'')-Benzyl-4-(cis-perhydroisoindol-2-yl)butyric acid
+| CAS_number_Ref = {{cascite|changed|??}}
-| image = Mitiglinide.svg
+| CAS_number = 145375-43-5
-| CAS_number = 207844-01-7
 | ATC_prefix = A10
-| ATC_suffix = BX
+| ATC_suffix = BX08
-| ATC_supplemental =
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
+| ChEMBL = 471498
 | PubChem = 121891
-| DrugBank =
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-| C = 19 | H = 25 | N = 1 | O = 3
+| DrugBank = DB01252
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 108739
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = D86I0XLB13
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D01854
+<!--Chemical data-->
+| C=19 | H=25 | N=1 | O=3
 | molecular_weight = 315.41 g/mol
-| bioavailability =
+| smiles = O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3
-| protein_bound =
+| InChI = 1/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1
-| metabolism =
+| InChIKey = WPGGHFDDFPHPOB-BBWFWOEEBF
-| elimination_half-life =
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
-| licence_JP = Glufast
+| StdInChI = 1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1
-| licence_US =
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
-| pregnancy_category =
+| StdInChIKey = WPGGHFDDFPHPOB-BBWFWOEESA-N
-| legal_status =
-| routes_of_administration = oral
 }}
+__NOTOC__
 {{SI}}
-'''Mitiglinide''' (trade name '''Glufast®''') is a [[drug]] for the treatment of [[type 2 diabetes]].
+{{CMG}}
+==Overview==
+'''Mitiglinide''' ([[International Nonproprietary Name|INN]], trade name '''Glufast''') is a [[drug]] for the treatment of [[type 2 diabetes]].<ref name="pmid18803455">{{cite journal |author=Malaisse WJ |title=Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients |journal=Expert Opin Pharmacother |volume=9 |issue=15 |pages=2691–8 |date=October 2008 |pmid=18803455 |doi=10.1517/14656566.9.15.2691 |url=http://www.informapharmascience.com/doi/abs/10.1517/14656566.9.15.2691}}</ref>
 Mitiglinide belongs to the [[meglitinide]] class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.  The North America rights to mitiglinide are held by Elixir Pharmaceuticals.  Mitiglinide has not yet gained [[Food and Drug Administration|FDA]] approval.
 ==Pharmacology==
-Mitiglinide is thought to stimulate [[insulin]] secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.
+Mitiglinide is thought to stimulate [[insulin]] secretion by closing the ATP-sensitive K(+) [[ATP-sensitive potassium channel|K(ATP) channels]] in pancreatic beta-cells.
 ==Dosage==
 Mitiglinide is delivered in tablet form.
+==References==
+{{reflist|2}}
 ==External links==
@@ Line 37: / Line 61: @@
 {{Oral hypoglycemics}}
-[[Category:Endocrinology]]
 [[Category:Meglitinides]]
+[[Category:Isoindoles]]
-{{WikiDoc Help Menu}}
+[[Category:Amides]]
-{{WikiDoc Sources}}

Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	oral
ATC code	A10BX08 (WHO)
Identifiers
IUPAC name (2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol- 2-yl]-4-oxobutanoic acid
CAS Number	145375-43-5^N
PubChem CID	121891
DrugBank	DB01252^Y
ChemSpider	108739^Y
UNII	D86I0XLB13
KEGG	D01854^Y
ChEMBL	ChEMBL471498^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₉H₂₅NO₃
Molar mass	315.41 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3
InChI InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1^Y Key:WPGGHFDDFPHPOB-BBWFWOEESA-N^Y
^NY (what is this?) (verify)